Spur Therapeutics

Spur Therapeutics is a late-stage clinical biotechnology company focused on developing life-changing gene therapies for debilitating chronic conditions.

By optimising every component of its product candidates, Spur aims to unlock the true potential of gene therapy to realise outsized clinical results. Spur is advancing a breakthrough gene therapy candidate for Gaucher disease, as well as a research strategy to move gene therapy into more prevalent diseases, including a pre-clinical programme in Parkinson’s disease.

Spur's lead programme, FLT201, is a highly differentiated gene therapy candidate that delivers a novel transgene to treat Gaucher disease Type 1, for which there is currently no cure. Spur has dosed the first patient in GALILEO-3, its Phase III pivotal trial of FLT201, following Phase I/II data showing encouraging improvements in skeletal disease, a major cause of morbidity in Gaucher patients. Spur's next generation gene therapy uses AAV technology that aims to deliver best-in-class safe and effective gene replacement to the liver to produce sustained therapeutic protein expression. Spur has additional pre-clinical research programmes in central nervous system (CNS) and cardiovascular diseases, including one focused on GBA1 Parkinson's disease that leverages the same novel transgene as FLT201. Michael Parini chairs the Board, while Chief Scientific Officer Henning Stennicke, PhD, has taken on the Chief Operating Officer role and leads the company's operations.